GlassScriptPhysician profile
Amy Ruth Ivy
NPI 1215799473
$1,044.99
in general payments reported to CMS, 2019-2025
16 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $939 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,044.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $176.65 | 2024 | Azstarys |
| Abbvie INC. | $161.08 | 2024-2025 | |
| Axsome Therapeutics, INC. | $141.57 | 2024 | Auvelity, Sunosi |
| Teva Pharmaceuticals USA, INC. | $123.33 | 2024 | Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $92.89 | 2024-2025 | Rexulti, Abilify Maintena |
| Validus Pharmaceuticals LLC | $63.40 | 2024 | Equetro |
| Neurocrine Biosciences, INC. | $54.12 | 2024 | Ingrezza |
| Lundbeck LLC | $43.77 | 2024 | Rexulti |
| Alkermes, INC. | $38.50 | 2024 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.59 | 2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $34.39 | 2024 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $23.47 | 2024 | Trintellix |
| Avadel Cns Pharmaceuticals, LLC | $14.15 | 2024 | Lumryz |
| Jazz Pharmaceuticals INC. | $13.98 | 2024 | |
| Neos Therapeutics, LP | $13.63 | 2024 | Adzenys Xr-Odt |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $13.47 | 2024 | Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Ivy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.